News Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
News Sanofi gets double blow for MS drug tolebrutinib Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.
News Roche's oral MS hope fenebrutinib hits the mark in phase 3 Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.
News Lilly eyes earlier use of blood cancer drug Jaypirca Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.
News Roche builds case for MS drug with two-year efficacy data Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.
News FDA starts review of Sanofi's MS hope tolebrutinib Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.
News Bankruptcy threat looms as Quince runs out of options Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
